Prophylactic Sclerotherapy for Esophageal Varices
Author Information
Author(s): H. Koch, K.F. Binmoeller, H. Grimm, N. Soehendra, H. Henning, G. Oehler
Primary Institution: Medical School, Cape Town, South Africa
Hypothesis
Does prophylactic sclerotherapy reduce the incidence of variceal bleeding and improve survival in patients with esophageal varices?
Conclusion
Prophylactic sclerotherapy reduces the occurrence of first variceal hemorrhage but does not improve survival.
Supporting Evidence
- Variceal bleeding occurred in 7% of sclerotherapy patients compared to 44% in control patients.
- Mortality rates increased with the severity of liver function impairment in both groups.
- Sclerotherapy did not improve survival regardless of cirrhosis etiology or variceal size.
Takeaway
Doctors tried a treatment to stop bleeding in patients with swollen veins in their throat, and while it helped prevent bleeding, it didn't help them live longer.
Methodology
Patients were randomly assigned to receive either prophylactic sclerotherapy or no treatment, with follow-up for bleeding and mortality.
Potential Biases
Potential selection bias in patient recruitment and varying operator experience.
Limitations
The study did not evaluate the impact of sclerotherapy on length of hospital stay or patient acceptability.
Participant Demographics
141 patients with esophageal varices and no prior gastrointestinal bleeding.
Statistical Information
P-Value
p < 0.01
Statistical Significance
p < 0.01
Want to read the original?
Access the complete publication on the publisher's website